Equities research analysts expect that Xencor Inc (NASDAQ:XNCR) will announce ($0.52) earnings per share (EPS) for the current quarter, according to Zacks. Four analysts have made estimates for Xencor’s earnings, with the lowest EPS estimate coming in at ($0.60) and the highest estimate coming in at ($0.44). Xencor posted earnings per share of ($0.32) during the same quarter last year, which would indicate a negative year-over-year growth rate of 62.5%. The business is scheduled to issue its next earnings results on Monday, February 24th.
On average, analysts expect that Xencor will report full year earnings of $0.50 per share for the current year, with EPS estimates ranging from $0.34 to $0.67. For the next financial year, analysts expect that the firm will post earnings of ($1.67) per share, with EPS estimates ranging from ($2.63) to ($0.43). Zacks’ EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Xencor.
Xencor (NASDAQ:XNCR) last released its quarterly earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.58) by $0.40. The business had revenue of $21.76 million during the quarter, compared to the consensus estimate of $4.62 million. Xencor had a return on equity of 5.84% and a net margin of 21.60%.
Several large investors have recently added to or reduced their stakes in the company. Parametric Portfolio Associates LLC lifted its position in shares of Xencor by 29.3% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 59,816 shares of the biopharmaceutical company’s stock worth $2,448,000 after buying an additional 13,553 shares during the last quarter. Comerica Bank bought a new stake in shares of Xencor during the 3rd quarter worth $1,610,000. Dupont Capital Management Corp bought a new stake in shares of Xencor during the 3rd quarter worth $339,000. First Trust Advisors LP bought a new stake in shares of Xencor during the 3rd quarter worth $2,472,000. Finally, Los Angeles Capital Management & Equity Research Inc. lifted its position in shares of Xencor by 64.6% during the 2nd quarter. Los Angeles Capital Management & Equity Research Inc. now owns 26,809 shares of the biopharmaceutical company’s stock worth $1,097,000 after buying an additional 10,520 shares during the last quarter. Hedge funds and other institutional investors own 92.43% of the company’s stock.
XNCR opened at $39.65 on Wednesday. The business has a fifty day simple moving average of $36.93 and a 200 day simple moving average of $37.41. The company has a market capitalization of $2.31 billion, a PE ratio of -30.27 and a beta of 1.38. Xencor has a 1 year low of $27.75 and a 1 year high of $46.33. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.92 and a quick ratio of 8.92.
Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and other protein therapeutics to treat severe and life threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions.
Featured Story: Liquidity
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.